News | June 27, 2021
Medicamen Biotech posts Rs. 3.64 Cr consolidated PAT in Q4FY21
The company has posted net profit of Rs.12.12 crores for the 12 months period ended March 31, 2021
The company has posted net profit of Rs.12.12 crores for the 12 months period ended March 31, 2021
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
Financial support is being provided as a grant from the Government of India
The agreement will help ensure wider reach and access to patients in India
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
